Altimmune (ALT)
(Delayed Data from NSDQ)
$7.57 USD
+0.48 (6.77%)
Updated Apr 23, 2024 04:00 PM ET
After-Market: $7.63 +0.06 (0.79%) 7:58 PM ET
3-Hold of 5 3
D Value D Growth F Momentum F VGM
Income Statements
Fiscal Year end for Altimmune, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 0 | 0 | 4 | 8 | 6 |
Cost Of Goods | 0 | 0 | 0 | 0 | 0 |
Gross Profit | 0 | 0 | 4 | 8 | 6 |
Selling & Adminstrative & Depr. & Amort Expenses | 96 | 88 | 101 | 63 | 27 |
Income After Depreciation & Amortization | -96 | -88 | -97 | -55 | -21 |
Non-Operating Income | 8 | 3 | 0 | 0 | 1 |
Interest Expense | 0 | 0 | 0 | 0 | 0 |
Pretax Income | -88 | -85 | -97 | -54 | -21 |
Income Taxes | 0 | 0 | 0 | -5 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -88 | -85 | -97 | -49 | -21 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -88 | -85 | -97 | -49 | -21 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -98 | -88 | -96 | -54 | -20 |
Depreciation & Amortization (Cash Flow) | -2 | 0 | 1 | 0 | 1 |
Income After Depreciation & Amortization | -96 | -88 | -97 | -55 | -21 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 53.25 | 46.93 | 41.28 | 25.64 | 13.13 |
Diluted EPS Before Non-Recurring Items | -1.43 | -1.81 | -2.07 | -1.91 | -0.98 |
Diluted Net EPS (GAAP) | -1.66 | -1.81 | -2.35 | -1.91 | -1.60 |
Fiscal Year end for Altimmune, Inc falls in the month of December .
All items in Millions except EPS data.
3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 | |
---|---|---|---|---|---|
Sales | NA | 0.04 | 0.36 | 0.01 | 0.02 |
Cost Of Goods | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | NA | 0.04 | 0.36 | 0.01 | 0.02 |
SG&A, R&D, and Dept/Amort Expenses | 0.00 | 21.24 | 22.90 | 18.01 | 21.78 |
Income After SG&A, R&D, and Dept/Amort Expenses | 0.00 | -21.20 | -22.54 | -18.00 | -21.76 |
Non-Operating Income | NA | 1.98 | 1.90 | 1.95 | 1.69 |
Interest Expense | NA | 0.00 | 0.03 | 0.00 | 0.00 |
Pretax Income | NA | -31.64 | -20.67 | -16.06 | -20.07 |
Income Taxes | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Minority Interest | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | NA | -31.64 | -20.67 | -16.06 | -20.07 |
Extras & Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | NA | -31.64 | -20.67 | -16.06 | -20.07 |
Earnings Per Share Data | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 |
---|---|---|---|---|---|
Average Shares | NA | 58.44 | 53.63 | 50.69 | 50.13 |
Diluted EPS Before Non-Recurring Items | NA | -0.33 | -0.39 | -0.32 | -0.40 |
Diluted Net EPS (GAAP) | NA | -0.55 | -0.39 | -0.32 | -0.40 |